The global economic downturn, impending blockbuster patent expiries and the wave of consolidation sweeping the pharmaceutical industry will drive demand for Patheon’s restructuring service according to CEO Wesley Wheeler.
Merck & Co is investing an additional €20m ($27m) in its biologics plant in Carlow, Ireland just weeks after it unveiled plans to create a “powerful biologics presence” through its $41bn move for fellow US drug giant Schering-Plough.
Vetter Pharma-Fertigung (VPF), a specialist provider of pre-filled injection systems, has formed a new subsidiary, Vetter Pharma International (VPI) to take charge of sales, marketing and customer services.
Michael Schmitt, president of Alcan Global Pharmaceutical Packaging, believes a recovery in the global economy, the increasing demand for quality and the emergence of markets like India and Brazil will be key drivers for the packaging sector over the...
Alastair Riddell, CEO of UK firm Stem Cell Sciences (SCS), says the US governments’ reversal of the ban on federally funded stem cell research “opens up a market that was inhibited, restrained and impeded under the Bush administration.”
The International Pharmaceutical Excipients Council (IPEC) – currently represented by divisions in Europe, the Americas, Japan and China – could see sister organisations open up in Latin America and India in the coming months.
The US green light for federally funded embryonic stem cell research is being hailed as a victory by the US drug industry, which predicts it will open the flood gates for novel medications and help revitalise the sector.
Two approvals in a week for drugs made at Ranbaxy’s New Jersey OHM Laboratories subsidiary have eased the generics firm’s North American regulatory woes and strengthened its position in the expanding US market.
Three plants owned by contract packaging maker Alcan have been cleared to produce containers for pharmaceutical products under the International Organization for Standardization’s ISO 15378:2006 guidelines.
Daiichi Sankyo, the Japanese drug firm that bought a controlling stake in India’s Ranbaxy last year, says it had no knowledge of FDA concerns that led to a block on ANDA reviews for drugs made at the latter’s Paonta Sahib facility.